HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.

TitleHIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.
Publication TypeJournal Article
Year of Publication2021
AuthorsCN Fries, J-L Chen, ML Dennis, NL Votaw, J Eudailey, BE Watts, KM Hainline, DW Cain, R Barfield, C Chan, MA Moody, BF Haynes, KO Saunders,, GG Fouda, and JH Collier
JournalScientific Reports
Volume11
Start Page14494
Issue1
Date Published07/2021
Abstract

A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, protective antibodies must be able to bind and neutralize a widely mutated viral envelope protein. No vaccine has yet been designed which induces broadly neutralizing or protective immune responses against HIV in humans. Nanomaterial-based vaccines have shown the ability to generate antibody and cellular immune responses of increased breadth and neutralization potency. Thus, we have developed supramolecular nanofiber-based immunogens bearing the HIV gp120 envelope glycoprotein. These immunogens generated antibody responses that had increased magnitude and binding breadth compared to soluble gp120. By varying gp120 density on nanofibers, we determined that increased antigen valency was associated with increased antibody magnitude and germinal center responses. This study presents a proof-of-concept for a nanofiber vaccine platform generating broad, high binding antibody responses against the HIV-1 envelope glycoprotein.

DOI10.1038/s41598-021-93702-x
Short TitleScientific Reports